Search - Myopathies inflammatoires & thérapies innovantes ciblées Access content directly

Filter your results

378 Results
Image document

Comparaison des caractéristiques et des pronostics des patients avec et sans cancer actif hospitalisés pour une infection à SARS-CoV-2

Charlotte Fenioux , Yves Allenbach , Aurore Vozy , Joe-Élie Salem , Georgina Maalouf , et al.
Bulletin du Cancer, 2021, 108 (6), pp.581-588. ⟨10.1016/j.bulcan.2021.03.004⟩
Journal articles hal-03830953v1

Vacuolar myopathy with monoclonal gammapathy and stiffness: A new Monoclonal gammopathy of muscle significance

Yves Allenbach , Emmanuelle Salort-Campana , Edoardo Malfatti , Bruno Eymard , Shahram Attarian , et al.
GCOM 2019 - Global Conference on Myositis 2019, Mar 2019, Berlin, Germany. , BMC Rheumatology Poster presentation n° P133, 3 (S1), pp.31, 2019, ⟨10.1186/s41927-019-0078-3⟩
Conference poster hal-03832060v1
Image document

Plasma exchange are not associated with better outcome in MDA5 rapidly-progressive interstitial lung disease

Pierre Bay , Marc Pineton de Chambrun , Vincent Rothstein , Matthieu Mahevas , Nicolas de Prost , et al.
French Intensive Care Society International Congress 2022, 2022, paris, France. pp.54, ⟨10.1186/s13613-022-01016-6⟩
Conference papers hal-03831253v1

Elucidating the molecular biology of Inclusion body Myositis through multi-omics analysis

Mridul Johari , Daphne Wijnbergen , Alaa Khan , Pedro Machado , Henry Houlden , et al.
Solve-RD, Solving the unsolved Rare Diseases, Final Meeting 2023, Apr 2023, Prague, Czech Republic
Conference poster hal-04086230v1

Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19

Noël Zahr , Saik Urien , Benoit Llopis , Valérie Pourcher , Olivier Paccoud , et al.
Therapies, 2021, 76 (4), pp.285-295. ⟨10.1016/j.therap.2021.01.056⟩
Journal articles hal-04073526v1

High Risk of Fatal and Non-Fatal Venous Thromboembolism in Myotonic Dystrophy

Maximilien Sochala , Raphaël Porcher , Tanya Stojkovic , Henri Marc Bécane , Anthony Béhin , et al.
6th International Congress of Myology, Mar 2019, Bordeaux, France
Conference poster hal-04020135v1
Image document

Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities

Yves Allenbach , Céline Anquetil , Ali Manouchehri , Olivier Benveniste , Olivier Lambotte , et al.
Autoimmunity Reviews, 2020, 19 (8), pp.102586. ⟨10.1016/j.autrev.2020.102586⟩
Journal articles hal-04003010v2
Image document

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Lee Nguyen , Marie Bretagne , Jennifer Arrondeau , Noel Zahr , Stephane Ederhy , et al.
Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩
Journal articles hal-04002766v1

Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol

Roberta Lorenzon , Encarnita Mariotti-Ferrandiz , Caroline Aheng , Claire Ribet , Ferial Toumi , et al.
BMJ Open, 2018, 8 (8), pp.e021037. ⟨10.1136/bmjopen-2017-021037⟩
Journal articles hal-04000044v1

JAK inhibitors for the treatment of adult dermatomyositis: A pilot study

Océane Landon-Cardinal , Perrine Guillaume-Jugnot , Ségolène Toquet , Nabiha Sbeih , Aude Rigolet , et al.
Journal of The American Academy of Dermatology, 2022, ⟨10.1016/j.jaad.2022.10.055⟩
Journal articles hal-03996988v1

Diagnostic yield of a practical electrodiagnostic protocol discriminating between different congenital myasthenic syndromes

Tanya Stojkovic , Marion Masingue , Helène Turmel , Marianne Hezode-Arzel , Anthony Béhin , et al.
Neuromuscular Disorders, 2022, 32 (11-12), pp.870-878. ⟨10.1016/j.nmd.2022.10.001⟩
Journal articles hal-03993811v1
Image document

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Lee Nguyen , Marie Bretagne , Jennifer Arrondeau , Noel Zahr , Stephane Ederhy , et al.
Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩
Journal articles hal-03832478v1

Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease

Pierre Bay , Marc de Chambrun , Vincent Rothstein , Matthiéu Mahevas , Nicolas de Prost , et al.
Journal of Autoimmunity, 2022, 133, ⟨10.1016/j.jaut.2022.102941⟩
Journal articles hal-03950145v1

Earlier Cancer Diagnosis after Idiopathic Inflammatory Myopathy Onset Is Associated with Improved Long Term Survival - Results from Four European Cohorts

Alexander Oldroyd , Paul New , Janine Lamb , William Ollier , Robert Cooper , et al.
American College of Rheumatology Convergence, ACR 2020 virtual, Nov 2020, NA, United States
Conference poster hal-03831570v1

Alpha-1-Antitrypsin Promoter Improves the Efficacy of an Adeno-Associated Virus Vector for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy

Raquel Cabrera-Pérez , Ferran Vila-Julià , Michio Hirano , Federico Mingozzi , Javier Torres-Torronteras , et al.
Human Gene Therapy, 2019, 30 (8), pp.985-998. ⟨10.1089/hum.2018.217⟩
Journal articles hal-03877796v1

Response to: Comment on “Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy”

Grégoire Monseau , Océane Landon-Cardinal , Anne-Marie Bouvier , Valérie Jooste , Achille Aouba , et al.
Journal of The American Academy of Dermatology, 2020, 83 (6), pp.e461-e462. ⟨10.1016/j.jaad.2020.07.110⟩
Journal articles hal-03831099v1

Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies

Kubéraka Mariampillai , Benjamin Granger , Damien Amelin , Marguerite Guiguet , Eric Hachulla , et al.
JAMA neurology, 2018, 75 (12), pp.1528-1537. ⟨10.1001/jamaneurol.2018.2598⟩
Journal articles hal-03831196v1

Response to: ‘Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria’ by Cavagna et al

James Lilleker , Jiri Vencovsky , Guochun Wang , Lucy Wedderburn , Louise Diederichsen , et al.
Annals of the Rheumatic Diseases, 2017, pp.annrheumdis-2017-212382. ⟨10.1136/annrheumdis-2017-212382⟩
Journal articles hal-03831184v1

Dermoskeletics to preserve mobility and function in inclusion body myositis

Océane Landon-Cardinal , François Prince , Stéphane Bédard , Olivier Benveniste , Marie Hudson
Neurology, 2018, 91 (16), pp.760-760. ⟨10.1212/WNL.0000000000006365⟩
Journal articles hal-03831176v1

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Michael Hanna , Umesh Badrising , Olivier Benveniste , Thomas Lloyd , Merrilee Needham , et al.
The Lancet Neurology, 2019, 18 (9), pp.834-844. ⟨10.1016/S1474-4422(19)30200-5⟩
Journal articles hal-03831123v1

Immune Checkpoint Inhibitor–Associated Myositis

Céline Anquetil , Joe-Elie Salem , Bénédicte Lebrun-Vignes , Douglas Johnson , Andrew Mammen , et al.
Circulation, 2018, 138 (7), pp.743-745. ⟨10.1161/CIRCULATIONAHA.118.035898⟩
Journal articles hal-03831164v1

224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.

Yves Allenbach , Andrew Mammen , Olivier Benveniste , Werner Stenzel , Anthony Amato , et al.
Neuromuscular Disorders, 2018, 28 (1), pp.87-99. ⟨10.1016/j.nmd.2017.09.016⟩
Journal articles hal-03831153v1

Mycophenolic acid area under the curve in patients with inflammatory myopathies

Marion Peyre , Noel Zahr , Quentin Riller , Fleur Cohen-Aubart , Yves Allenbach , et al.
Rheumatology, 2021, 60 (6), pp.3026-3028. ⟨10.1093/rheumatology/keab167⟩
Journal articles hal-03830972v1

Inclusion Body Myositis in 2022: from physiopathogenesis to clinical trials

Olivier Benveniste
4th Global Conference On Myositis,, Jun 2022, Prague, Czech Republic
Conference papers hal-03864190v1

Treatment Options for Idiopathic Inflammatory Myopathies

Olivier Benveniste
17th International Congress on NeuroMuscular Diseases, Jul 2022, Bruxelles, Belgium
Conference papers hal-03864178v1

Inflammatory Myopathies and Innovative Therapies

Olivier Benveniste
TMA’s Annual Patient Conference, Sep 2022, Orlando, United States
Conference papers hal-03864169v1

Les myopathies inflammatoires en 2022 : de la physiopathologie aux traitements ciblés

Olivier Benveniste
17ème Journées Scientifiques de la Société Tunisienne d’Immunologie, Nov 2022, Hammamet, Tunisie
Conference papers hal-03864162v1

Refractory myositides.

Olivier Benveniste
XVIth UCLouvain Review Course on Systemic Rheumatic Diseases, Nov 2022, Bruxelles, Belgium
Conference papers hal-03864159v1

Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’

Cloé Comarmond , Mathilde Leclercq , Gaëlle Leroux , Cindy Marques , Alexandre Le Joncour , et al.
Annals of the Rheumatic Diseases, 2020, pp.annrheumdis-2020-219407. ⟨10.1136/annrheumdis-2020-219407⟩
Journal articles hal-03831033v1

IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans

A Nguyen , Y Repesse , M Ebbo , Y Allenbach , Olivier Benveniste , et al.
Clinical and Experimental Immunology, 2021, 204 (2), pp.258-266. ⟨10.1111/cei.13580⟩
Journal articles hal-03830962v1